The vaccine is Pharmaq's first against Infectious Salmon Anaemia (ISA) and will be a significant contribution to the Chilean fish farmer’s fight against this devastating disease, which struck the industry in 2007, says the company.
To help and rebuild a sustainable Chilean salmon industry, PHARMAQ established an extensive ISA project in 2007. Investment in this project has reached nearly 40 million NOK.
"This proves our targeted focus in development of ISA vaccines to the industry," said Morten Nordstad, CEO of PHARMAQ.
ALPHA JECT® micro 1 ISA is a single-component ISA vaccine. In addition, an application for a multi-component ISA vaccine from PHARMAQ has also been submitted to the Chilean authorities.
"We hope to receive an approval of the multi-component vaccine for Chile in the near future. Within PHARMAQ there is a wide basis of competence and knowledge of the ISA virus and vaccine development. Based on this result, our next objective will be to include the well documented ISA vaccine component into vaccines for the fish farming industry in Norway and the Faroe Islands. First of all, today we are proud to offer an ISA vaccine to our Chilean customers," MrNordstad concluded.
ISA Vaccine Approved In Chile
NORWAY/ CHILE - PHARMAQs vaccine ALPHA JECT micro 1 ISA received a provisional marketing authorisation from the Chilean authorities Servicio Agrcola y Ganadero de Chile, on April 15th.
